GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.
Level 3 - non-randomized controlled study
Retrospective propensity score-matched cohort study (target trial emulation)
PubMed 42252247 · doi:10.1016/j.annonc.2026.04.013
What was done
A target trial emulation cohort study evaluated the association between GLP-1 receptor agonist (GLP-1RA) use and the risk of 13 obesity-associated cancers (OACs) in obese, nondiabetic adults without prior OAC, using the US TriNetX electronic health records database (December 2014 to June 2025). Patients prescribed GLP-1RAs were compared to patients receiving diet or exercise counseling using 1:1 propensity score matching and inverse probability of treatment weighting. Secondary subgroup analyses evaluated sex, body mass index (<40 vs. ≥40 kg/m²), race (White vs. Black), and specific drug (semaglutide vs. tirzepatide).
What was found
From an initial cohort of 229,467 patients, 161,798 matched participants (80,899 GLP-1RA users and 80,899 lifestyle counseling controls; mean age 47.2 years) were analyzed over a median follow-up of 2 years (interquartile range 1–2 years). GLP-1RA use was associated with a significantly lower cumulative incidence of any OAC compared with lifestyle counseling (hazard ratio 0.59, 95% CI 0.53–0.67). Subgroup analyses showed consistent risk reductions across sex, BMI categories, and drug types, but not among Black patients.
Why it matters
This study extends evidence for the potential oncologic benefits of GLP-1RAs beyond diabetes, showing an association with reduced short-term risk of obesity-related cancers in obese, nondiabetic adults.
Limits
The study is observational and vulnerable to residual confounding despite propensity matching. Follow-up was short (median 2 years) for assessing cancer outcomes, the protective association did not reach significance in Black patients, specific cancer subtypes were not broken down in the abstract, and prospective trials are needed to confirm causality.
Cited by
- supports Studies show that GLP-1 receptor agonists are protective to some degree against obesity-related cancers.